Williams & Connolly successfully represented Teva Pharmaceuticals International GmbH in a patent infringement action under the Hatch-Waxman Act relating to Teva’s Bendeka®, a drug with more than $2 billion in cumulative sales used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. After a seven-day bench trial held last September, on April 27th the U.S. District Court for the District of Delaware upheld the validity of all asserted claims in all asserted patents and found that the defendant generic manufacturers infringed or induced infringement of each of the asserted claims.
The team representing Teva includes David Berl, Adam Harber, Elise Baumgarten, Shaun Mahaffy, Ben Picozzi, and Matthew Lachman.
Click here to read Law360's coverage of the case. The win was also featured at the top of Law360's "Legal Lions" list.